Reed NewsReed News
Location

Sysslebäck

Semaglutide-NAION Risk Debate Amid Patient Insurance Rejection
Health·17h sedan

Semaglutide-NAION Risk Debate Amid Patient Insurance Rejection

A patient in Sweden nearly lost vision in both eyes after semaglutide treatment, sparking debate over the drug's link to a rare eye condition, as studies show inconsistent risk signals. Her insurance claim was rejected, citing obesity as a factor, though medical experts challenge this assessment.

← Back to Explore